DASH to Protect Antibiotics

Website

DASH to Protect Antibiotics A Global Initiative for Antimicrobial and Diagnostic Stewardship

23/09/2026

🎥 Press play for an exclusive preview!

The highly anticipated International Symposium on Antimicrobial Stewardship and One Health is fast approaching, and we welcome you to register.

🗓️ When: Saturday, 31st October 2026
🔗 Register here: https://lnkd.in/dM2ZA2Ea

We are deeply honoured to host a lineup of renowned global experts for state-of-the-art keynotes from Prof. David Livermore (UK), Dr. Timothy Rawson (UK), Dr. Priscilla Rupali (India), and Dr. Wael ElAmin (UAE).

Our speakers will tackle some of the most pressing challenges:
🔹 In-vitro susceptibility versus in-vivo outcomes.
🔹 Transitioning from rapid results to early action in bloodstream infections.
🔹 Real-world case studies on optimizing duration and de-escalation in sepsis.
🔹 How Artificial Intelligence is revolutionizing the fight against AMR.

Our illustrious moderators will expertly guide dynamic discussions: Dr. Raman Sardana (India), Dr. Amina Al Jardani (Oman), Dr. Afreenish Amir (Pakistan), and Dr. Katia Iskandar (Lebanon). We are also incredibly grateful to have the DASH to Protect P*s joining us to share their expertise as resource persons.

Looking forward to having a great galaxy of august audience join us at this exciting event!

👉 Please register with the following link: https://lnkd.in/dM2ZA2Ea

Please make sure to enter the event with the same email with which you had registered in order to attend the event and avail of the certificates.

23/09/2026





🎥 Press play for an exclusive preview!

The highly anticipated International Symposium on Antimicrobial Stewardship and One Health is fast approaching, and we welcome you to register.

🗓️ When: Saturday, 31st October 2026
🔗 Register here: https://lnkd.in/dM2ZA2Ea

We are deeply honoured to host a lineup of renowned global experts for state-of-the-art keynotes from Prof. David Livermore (UK), Dr. Timothy Rawson (UK), Dr. Priscilla Rupali (India), and Dr. Wael ElAmin (UAE).

Our speakers will tackle some of the most pressing challenges:
🔹 In-vitro susceptibility versus in-vivo outcomes.
🔹 Transitioning from rapid results to early action in bloodstream infections.
🔹 Real-world case studies on optimizing duration and de-escalation in sepsis.
🔹 How Artificial Intelligence is revolutionizing the fight against AMR.

Our illustrious moderators will expertly guide dynamic discussions: Dr. Raman Sardana (India), Dr. Amina Al Jardani (Oman), Dr. Afreenish Amir (Pakistan), and Dr. Katia Iskandar (Lebanon). We are also incredibly grateful to have the DASH to Protect P*s joining us to share their expertise as resource persons.

Looking forward to having a great galaxy of august audience join us at this exciting event!

👉 Please register with the following link: https://lnkd.in/dM2ZA2Ea

Please make sure to enter the event with the same email with which you had registered in order to attend the event and avail of the certificates.

Ladies and Gentlemen The much awaited International Symposium on Antimicrobial Stewardship and One Health is coming u...
23/08/2026





Ladies and Gentlemen

The much awaited International Symposium on Antimicrobial Stewardship and One Health is coming up soon!
Please mark the date: Saturday, 31st October 2026.

Link: https://in.eregnow.com/ticketing/register/ISASOH2026

We are hugely honored to host veritable titans who will deliver state of art talks: Prof. David Livermore, (United Kingdom), Dr. Timothy Rawson, (United Kingdom), Prof. Dr Priscilla Rupali, (India); Dr Wael Amin (Dubai)
We welcome the global community to join us and hear them expound on state of art topics:
• In-vitro susceptibility versus in-vivo outcome.
• Antimicrobial Stewardship in Bloodstream Infection: From Rapid Results to Early Action.
• Optimizing Duration and De-escalation in Sepsis and Bloodstream Infection- a few case studies.
• Code vs. Bacteria: How Artificial Intelligence is Reshaping the Battle Against AMR.

The illustrious moderators Prof. Raman Sardan, (India) Dr Amina Al Jardani,(Oman), Dr Afreenish Amir, (Pakistan), Dr Katia Iskandar (Lebanon), will add zing to the event through their incisive comments.

The DASH to Protect P*s will add glitter to the event as resource persons.

Looking forward to having a galaxy of august audience join us at this exciting event!

The event is online.

Registration is free thanks to our sponsors.

Please register with the following link:
https://in.eregnow.com/ticketing/register/ISASOH2026

Please make sure to enter the event with the same email with which you had registered in order to attend the event and avail of the certificates.

🔹About Andes Virus⬩ Definition: A highly severe, specific strain of hantavirus native to South America.⬩ The Danger» Pro...
20/05/2026

🔹About Andes Virus
⬩ Definition: A highly severe, specific strain of hantavirus native to South America.
⬩ The Danger
» Progresses rapidly
» High mortality rate (35% to 40%)
🔹What It Causes
⬩ Primary Condition: leading cause of Hantavirus Cardiopulmonary Syndrome (HCPS / HPS).
⬩ Severe Complications: The virus causes lung capillaries to leak fluid, triggering acute respiratory failure, fluid accumulation in the lungs (pulmonary edema), and severe hemodynamic shock.
🔹How It Transmits to Humans
⬩ Zonootic (Animal-to-Human)
Primarily contracted by inhaling aerosolized virus particles from the urine, f***s, or saliva of infected wild rodents, specifically the long-tailed pygmy rice rat.
⬩ Human-to-Human
Andes virus is the only hantavirus capable of spreading person-to-person. It requires prolonged, close contact or exposure to the bodily fluids of a symptomatic individual.
⬩ Recent Cruise Outbreak
A 2026 outbreak onboard the cruise ship MV Hondius showcased this rare human-to-human transmission. An initial patient caught the virus in Patagonia from a landfill site and subsequently passed it to others in the ship's close, enclosed quarters.
🔹Symptoms
⬩ The incubation period can last up to 42 days, with illness presenting in two distinct phases:
⬩ Early Phase (Flu-like): Sudden fever, fatigue, severe muscle aches (especially in the thighs, hips, and back), headaches, and occasional gastrointestinal issues like vomiting or diarrhea.
⬩ Late Phase (Cardiopulmonary): Coughing, intense shortness of breath, chest tightness, and a rapid descent into respiratory failure as the lungs fill with fluid.
🔹Basic Case Numbers World Over
⬩ Historical Baseline: Prior to 2026, the virus was considered rare, with only a few hundred cases ever diagnosed, mostly isolated to rural Chile and Argentina.
⬩ 2026 Cruise Cluster: The recent international maritime outbreak has accounted for 11 to 12 cases globally (including 9 fully confirmed) and resulted in 3 deaths.
⬩ Regional Spike: Separate from the cruise ship, Argentina has seen a sharper seasonal spike on land, recording over 100 cases in their recent 2025 - 2026 tracking season.

Therapeutic Alternatives for Acinetobacter baumannii (CRAB):🔸 Sulbactam-Durlobactam.Inhibits >96% of CRAB isolates inclu...
17/05/2026

Therapeutic Alternatives for Acinetobacter baumannii (CRAB):

🔸 Sulbactam-Durlobactam.
Inhibits >96% of CRAB isolates including those resistant to colistin, imipenem, and ciprofloxacin making it the first agent to demonstrate a mortality benefit in a dedicated CRAB trial.

🔸 Cefiderocol.
A siderophore cephalosporin with potent in vitro CRAB activity; real-world data show cefiderocol-containing regimens carry significantly lower 30-day mortality than colistin-based therapy (34% vs. 55.8%).

🔸 Ampicillin-Sulbactam + Meropenem + Polymyxin B.
A high-sulbactam-dose triple combination (sulbactam 9g/day) used where newer agents are unavailable.

🔸 Eravacycline.
A synthetic fluorocycline with lower MICs against CRAB than tigecycline, eravacycline evades classical tetracycline efflux pumps.

🔸 Tigecycline.
A glycylcycline with broad-spectrum CRAB coverage but plagued by low serum levels and high volume of distribution, making it inadequate as monotherapy for bacteraemia.

🔸 Polymyxin B.
A last-resort agent with rapid bactericidal activity against CRAB via membrane disruption; colistin monotherapy clinical failure rates reached 83% in one trial, with 28-day mortality of 46%, establishing that polymyxin monotherapy has no role if used, it must be part of a combination regimen with dose optimisation to overcome serum level variability and poor lung pe*******on.

🧼 Who Are the Propellors of Change for Hand Hygiene? | Effective hand hygiene doesn't happen in isolation. It requires ...
11/05/2026

🧼 Who Are the Propellors of Change for Hand Hygiene? |

Effective hand hygiene doesn't happen in isolation. It requires a coordinated effort across healthcare systems and communities alike.

In the healthcare sector, our focus spans:
🏥 Public Sector: Specialized care at large Centers of Excellence and tertiary hospitals
🏘️ District & Community Facilities: District hospitals, primary health centers & Anganwadi centers
💊 Small & Informal Providers: Nursing homes, GPs, alternate medicine & informal practitioners
🏢 Private Sector: High-volume facilities, including Centers of Excellence

Beyond the clinic, change begins in the community:
📡 Media: Amplifying expert advice to national audiences instantly
📱 Social Media: Driving viral change through influencers and creative challenges
👥 General Population: Normalizing frequent handwashing through collective peer influence
🎓 Educational Institutes: Embedding proper hand hygiene techniques in students early to build lifelong habits

From hospitals to classrooms, from screens to communities, hand hygiene is everyone's responsibility.

Together, we can DASH toward a future where clean hands protect lives and preserve the power of antibiotics. 💪

Happy World Hand Hygiene Day 2026! 🌍The most powerful weapon against AMR isn't a new drug, it's soap and water.We're rem...
05/05/2026

Happy World Hand Hygiene Day 2026! 🌍

The most powerful weapon against AMR isn't a new drug, it's soap and water.
We're reminding the world that clean hands are the first line of defense against the antibiotic resistance crisis. No lab. No prescription. No cost barrier.

Low-tech. High-impact. 🧼
Hand hygiene is the most cost-effective infection prevention tool we have, whether you're in a world-class hospital or a school classroom. The barrier isn't technology. It's awareness.

Clean hands slow resistance. 🛡️
Every time we stop a pathogen from spreading, we reduce the need for antibiotics. And every antibiotic we don't overuse is one that still works when we need it most.

The maths is simple:
Fewer infections → Fewer prescriptions → Antibiotics that last. 💊

The future of medicine starts with a 20-second habit. Let's protect it.

👇 Share this with someone who needs the reminder.

Once inside a host, A. baumannii uses advanced nutrient acquisition systems to scavenge essential metals like iron and z...
04/05/2026

Once inside a host, A. baumannii uses advanced nutrient acquisition systems to scavenge essential metals like iron and zinc. Coupled with metabolic adaptability and robust stress response pathways, the pathogen remains resilient even in nutrient-limited environments.

Acinetobacter baumannii is officially classified as a Global Priority 1 Threat. This hardy, Gram-negative bacterium has ...
03/05/2026

Acinetobacter baumannii is officially classified as a Global Priority 1 Threat. This hardy, Gram-negative bacterium has earned the title of "superbug" due to its extensive resistance to most standard antibiotics and its ability to cause serious infections in healthcare settings, particularly among the critically ill.

A major challenge is its environmental persistence. It exhibits high desiccation tolerance and the ability to form biofilms, allowing it to survive for long periods on dry hospital surfaces and medical devices. It can even enter a "VBNC" (viable but non-culturable) state to withstand disinfection.

Acinetobacter baumannii: A Critical Challenge in Antimicrobial ResistanceAcinetobacter baumannii is classified as a Glob...
29/04/2026

Acinetobacter baumannii: A Critical Challenge in Antimicrobial Resistance

Acinetobacter baumannii is classified as a Global Priority 1 Threat due to its extensive resistance to standard therapeutic options. This hardy, Gram-negative bacterium is a notorious "superbug" in healthcare settings, capable of prolonged survival on dry surfaces and primarily affecting critically ill or immunocompromised patients.Its pathogenesis is driven by a sophisticated array of virulence factors, including:Biofilm formation on medical devices and abiotic surfaces.

Regional data highlights a severe burden, with Carbapenem-Resistant A. baumannii (CRAB) accounting for up to 70-90% of ICU isolates in certain areas, leading to crude mortality rates exceeding 40-60% in ventilated patients.Understanding these mechanisms is vital for developing effective clinical interventions and antimicrobial stewardship protocols.

Address

Muscat

Website

Alerts

Be the first to know and let us send you an email when DASH to Protect Antibiotics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category